Here you’ll find everything you need to know from MM&M’s February 2017 issue, including our payer state of the union, social media spotlight, and more.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn’t want you to see the damn thing.
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
Pharma and biotech can bolster their value through the analytics efforts of their health economics and outcomes teams.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.
It’s hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
One pharmacy director would like to see a lot more comparative data about new therapies.
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
Get the most out of
Register for free and enjoy unlimited access to:
